JPRN-UMIN000008398已完成2 期
Phase II study of Erlotinib for previously treated advanced or recurrent non-small-cell lung cancer with EGFR wild type and KRAS wild type - Phase II study of Erlotinib for previously treated advanced or recurrent non-small-cell lung cancer with EGFR wild type and KRAS wild type
Gunma Uninersity Hospital0 个研究点目标入组 30 人开始时间: 2012年7月11日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Patients with active lung disease such as interstitial pneumonia, pneumoconiosis, active radiation pneumonitis, or drug-induced pneumonitis 2)Cases with past history of administration of HER related agents 3)4) Patients having EGFR mutation (exon 18,19,20,21) 4)Patients with gastrointestinal disorders 5)Patients with active opthalmological disease 6)Patients with spinal cord compression syndrome 7)Patients with symptomatic brain 8)Patients with active severe infections 9)Patients with active cardiac disease 10)Patients with severe clinical symptom 11)Patients active concomitant malignancy 12)Severe psychological disease 13)Pregnant or breast-feeding females or those who declined contraception 14)Inappropriate patients for this study judged by the attending physician
研究者
相似试验
已完成
2 期
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutatioon-small cell lung cancerJPRN-UMIN000002716Central Japan Lung Study Group (CJLSG)29
已完成
2 期
A Phase II Study of Erlotinib for previously treated Non-small cell Lung Cancer Patients without Epidermal Growth Factor Receptor Mutatioon-small cell lung cancerJPRN-UMIN000002692Central Japan Lung Study Group (CJLSG)54
招募中
2 期
A Phase II Study of Erlotinib for previously treated Non-Small Cell Lung Cancer PatientsObjective of the study is to investigate efficacy and safety of Erlotinib for previously treated non-small cell lung cancer patients.JPRN-UMIN000004680Tottori University, Faculty of Medicine,Division of Medical Oncology and Molecular Respirology Department of Multidisciplinary Internal Medicine27
已完成
2 期
Phase II study of erlotinib in previously treated non-small cell lung cancer (NSCLC) with wild type EGFR(NEJ006/TCOG0903)Pre-treated non-small cell lung cancer with wild type EGFR and occurred in never or light smokerJPRN-UMIN000002795orth East Japan Study Group /The Tokyo Cooperative Oncology Group43
已完成
2 期
Phase II study of Erlotinib in previously treated advanced non-small cell lung cancer patients with carcinomatous meningitison-small cell lung cancerJPRN-UMIN000007020ung Oncology Group in Kyushu, Japan (LOGIK)32